adults is about 10%, 3 increasing to 26% in unselected patients with non-valvular AF. 4 Importantly, AF in patients with CKD is associated with the progression of CKD, cardiovascular morbidity and mortality rates. 5 Patients with CKD have an increased risk of thrombosis and concurrently, are at greater risk of bleeding, proportional to the decrease in estimated glomerular filtration rate (eGFR). 6 In addition to CKD, other independent variables increase the risk of hemorrhage in patients receiving vitamin K antagonists (VKA), especially poor quality anticoagulation and potentially reversible bleeding risks within the HAS-BLED score. ) or in renal replacement therapy. 9 This probably relates to difficulties in maintaining optimum control with standard anticoagulant therapies that has generally narrow therapeutic margins. 10 One way to assess anticoagulation control is by calculating the time in therapeutic range (TTR) for the international normalized ratio (INR) between 2 and 3.
11 Good TTR (>65%-70%) has been associated with lower risks of thromboembolism and bleeding.
12
Currently, the National Institute for Health and Care Excellence (NICE) guidelines 13 and the Spanish Ministry of Health 14 have set a threshold of 65% as the indicator of good anticoagulation control.
In clinical practice, having predictors of both good or poor control provides adequate monitoring strategies and opens investigations into other possible treatment options, such as the non-VKA oral anticoagulants.
Several factors associated with TTR control have been identified, such as age, sex, race, smoking status, other comorbidities, dietary patterns and/or the use of drugs and medications. In addition, a point system has been proposed for individual patients, such as the SAMe-TT 2 R 2 score [15] [16] [17] (Table S1 ). A SAMeTT 2 R 2 score >2 is associated with labile INR control. Because CKD is linked to other factors such as advanced age, diabetes mellitus, uncontrolled hypertension and cardiovascular disease, the information available about the true impact of CKD on the control of TTR is limited.
10,12
In a sub-analysis of the PAULA study, 18, 19 we reported the discriminative ability of the SAMe-TT 2 R 2 score and three additional factors as predictors of a TTR <65% were identified: dietary pattern, risk of bleeding and polypharmacy. Although CKD was included in comorbidities from the data obtained from the subjects' medical history, this carried a relatively low weight on the predictive value of the SAMe-TT 2 R 2 score, as clinical records may underestimate CKD in comparison to an ad hoc estimate of renal function employing the appropriate equations.
3,20
The aim of this study was to evaluate the association between impaired renal function (eGFR <60 mL/min/1.73 m 2 ) and anticoagulation control in patients with non-valvular AF on VKA therapy, from the PAULA study. 18 We also assessed whether the predictive value of the SAMe-TT 2 R 2 score prevailed for subgroups both with and without impaired renal function.
| METHODS
This observational, cross-sectional, retrospective and nationwide multicenter study was carried out from February 2014 to October 2014 and using data from the PAULA cohort. 18 The study was 
18,19
The study involved 139 primary care physicians from 99 healthcare centers across Spain. The main criteria for patient inclusion have been reported. 18, 19 For this study, we included only those PAULA
18
patients who had at least one recent creatinine blood test available (<6 months old), as well as the TTR data.
| Quality of anticoagulation control
The calculations for the TTR were made centrally for the last ) presents a favorable benefit/risk profile.
What′s new
• CKD is associated with poor control of anticoagulation in patients with non-valvular AF taking vitamin K antagonist therapy since a progressive reduction in time in therapeutic range was observed as renal function worsened.
• The SAMe-TT 2 R 2 score has not shown a significant predictive value for determining the quality of anticoagulation control in the subgroup of AF patients with CKD.
| Renal function
Renal function was based on the eGFR using the modified diet and renal disease (MDRD) study equation. 
| Clinical variables and risk scores
The following variables were collected in the inclusion visit: demo- 
| Statistical analysis
For the descriptive analysis, quantitative variables were described with measures of central tendency and dispersion (mean, SD) and qualitative variables were described as absolute (n) and relative (%) A linear regression analysis was performed with factors that reached a significance level of P<.25 to identify the independent predictive factors associated with the anticoagulation quality level in patients with CKD or preserved renal function.
The discriminative capability of the SAMe-TT 2 R 2 score was also measured in patients with CKD or preserved renal function using the receiver operating characteristic curve, with the TTR defined as the dependent variable and the SAMe-TT 2 R 2 score as the independent variable, and the area under the curve (AUC) was calculated. We used the same cut-off point for the SAMe-TT 2 R 2 score as our previous study (0-1/≥2), 19 and 0-2/≥3, the cut-off point used by other 
| RESULTS
Of the 1524 patients included in the PAULA study, 18 data were available in 1381 patients, allowing calculation of the eGFR (Figure 1 ). Baseline characteristics of both subgroups are shown in Table 1 .
Patients with CKD were older, a more likely to be female and had more comorbidities than non-CKD patients. CKD patients had a greater prevalence of polypharmacy, showed a higher mean stroke and bleeding risk scores and mean SAMe-TT 2 R 2 score and the proportion with score≥2 were higher in CKD patients (P<.05).
In total, 20 245 INRs available were analyzed (an average of 14.5
readings per patient). CKD patients had worse levels of anticoagulation control. Anticoagulation control levels progressively worsened across each stage of CKD for TTR and other control variables (e.g. time below and above range and INR variability). The SAMe-TT 2 R 2 score was significantly increased with the degree of worsening renal function (Table 2) . .449 (Continues) (Table 3) .
| Predictors of anticoagulation control
Regarding sex differences (Table S3) , there was no difference in the mean age or the eGFR. Women, when compared to men, had a higher prevalence of hypertension (P=.031) and fewer comorbidities (P=.001), especially those related to ischaemic heart disease (P=.007).
These were related to differences in stroke and bleeding risk scores. No significant interaction was observed between CKD and sex (P=.306). 
| DISCUSSION
In this study, we show that eGFR below 60 mL/min/ .027
SAMe-TT T A B L E 1 (Continued) evident in those without CKD. Finally, the proportion of females with TTR ≥65% was significantly lower compared to males.
The degree of anticoagulation control was suboptimal in 40% of the cases (TTR <65%), a similar percentage to that found in recent studies. 25 We prospectively estimated renal function using the MDRD-4 equation, instead of relying on the clinical recording of the diagnosis of "renal inssufficiency", which has been used for some predictive clinical scores including the SAMe-TT 2 R 2 .
We found a prevalence of CKD in our patients of 26.8%. This figure is higher than figures reported in recent studies in patients with AF within the specialist cardiology service, where individuals were often younger with a lower percentage of female subjects. 25, 26 However, the prevalence of CKD we found was similar to that in other large studies using systematic measurements of eGFR, which ensures better definition of actual renal function. 12 As we reported in the previous PAULA study, 19 clinically recorded CKD diagnosis was only 6.8%. In this study, the prevalence of CKD was fourfold higher when eGFR was systematically calculated for each patient, which highlights the important suboptimal detection of CKD in clinical practice, with possible clinical consequences.
3
More than 90% of our CKD patients had moderate CKD (stages 3A or 3B), based on the current KDIGO classification. 20 Patients with CKD were older, there was a higher proportion of females, more comorbidities, more polypharmacy and increased embolic and bleeding risks, similar to results in other studies.
1,6
Importantly, eGFR <60 mL/min/1.73 m 2 was an independent predictor of poor anticoagulation control that persisted even after adjustments were made for other clinical variables. The presence of CKD alone increased the probability of suboptimal control (TTR <65%) by 28.4%. The presence of CKD was negatively associated with reaching a TTR ≥65%. The SAMe-TT 2 R 2 score lost its discriminative capacity for poor TTR in the subgroup of CKD, but this could be due to the small sample size (n=370). Nevertheless, previous literature shows the SAMe-TT 2 R 2 had a significant, although modest, ability to assess the likelihood of poor INR control, with the C index varying from 0.54 to 0.5819. 17, 19 Thus, under the specific conditions of this study a reduction in the discriminative capacity may be expected. In the previous study from the PAULA cohort, 19 which evaluated the predictive ability of the SAMe-TT 2 R 2 , we found a significant association between low TTR and some clinical factors. In patients with CKD, none of these factors were found to be significant, which could also reflect the smaller sample size. According our results, a modified SAMe-TT 2 R 2 score according to eFGR should be investigated for patients with CKD.
A decline in eGFR was linearly associated with a worse TTR, as well as to a longer time below and above the therapeutic INR range, as well as an increased INR variability as renal function worsened. As expected, the risk of bleeding in the CKD subgroup was significantly higher than for the others. Recently, García-Fernández et al. 7 showed that after 3-year follow-up, that the presence of CKD increased the risk of major bleeding (and up to sixfold the risk of mortality) in Finally, female sex was predictor of poor control of TTR in patients with CKD. There was no evidence of significant interaction between decreased eGFR and sex, so the CKD behaved as an independent predictor of TTR in both men and women. Nonetheless, the proportion of females with TTR ≥65% was significantly lower compared with males, which may explain why stroke rates in anticoagulated AF patients are higher in females than males. Our main limitation was the retrospective design, as predictive risk factors and scores such as SAMe-TT 2 R 2 should be evaluate patients prior to initiating treatment. Due to the sample size and limited follow-up no major hemorrhage or cardiovascular events were reported in our study. However, we analyzed the relationship between the presence of CKD with INR variability which is important since INR variability is a good predictor of cardiovascular events, perhaps even more powerful than the TTR. 28, 29 Although most were treated with acenocumarol, there are no differences in anticoagulation control and cardiovascular events between acenocumarol and warfarin. 30 The standard definition of CKD is based on at least two measurements of eGFR performed 3 months apart and the albuminuria measurement. However, the diagnosis of CKD in this study was based on a single eGFR measurement for practical reasons. The applicability of our results to other populations, with relevant ethnic, cultural or treatment variations, is an a priori limitation and must be addressed in other studies.
| CONCLUSIONS
In conclusion, CKD is associated with poor control of anticoagulation in patients with non-valvular AF taking VKA since a progressive reduction in TTR was observed as renal function worsened. The T A B L E 3 Assessment of SAMe-TT 2 R 2 score to predict TTR <65% SAMe-TT 2 R 2 score was not predictive of poor TTR in the subgroup with CKD, although a modest predictive value for poor TTR was found in those without CKD. Poor anticoagulation control (TTR <65%) was significantly greater among females.
